Passage BIO, Inc. (PASG) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PASG currently has 3.21M outstanding shares. with significant dilution risk as 2.44M authorized shares could dilute existing holders by 76.1%. The company has minimally diluted shareholders by 5.68% over the past 2 years. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 3.2M shares outstanding |
3.2M | 2.4M |
| Nov 10, 2025 |
10-Q filing | 3.2M shares outstanding |
3.2M | 2.4M |
| Aug 12, 2025 |
10-Q filing | 3.2M shares outstanding |
3.2M | 2.4M |
| Jul 14, 2025 |
Stock Split
8-K filing: Stock split 1-for-20 | Outstanding: 62,109,991 → 3,120,295 |
3.1M | 2.4M |
| May 13, 2025 |
10-Q filing | 62.1M shares outstanding |
62M | 49M |
| Mar 04, 2025 |
10-K filing | 60.4M shares outstanding |
60M | 49M |
| Nov 13, 2024 |
10-Q filing | 61.8M shares outstanding |
62M | 49M |
| Aug 08, 2024 |
10-Q filing | 61.7M shares outstanding |
62M | 49M |
| May 14, 2024 |
10-Q filing | 56.3M shares outstanding |
56M | 49M |
| Mar 04, 2024 |
S-3 filing: The company may offer up to $200,000,000 aggregate dollar amount of shares of its common stock or preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities. |
55M | 49M |
| Mar 04, 2024 |
10-K filing | 54.7M shares outstanding |
55M | 49M |
| Nov 13, 2023 |
10-Q filing | 54.8M shares outstanding |
55M | 20M |
| Aug 07, 2023 |
10-Q filing | 54.7M shares outstanding |
55M | 20M |
| May 11, 2023 |
10-Q filing | 54.6M shares outstanding |
55M | 20M |
| Mar 06, 2023 |
10-K filing | 54.4M shares outstanding |
54M | 20M |
| Nov 10, 2022 |
10-Q filing | 54.5M shares outstanding |
54M | 20M |
| Aug 04, 2022 |
10-Q filing | 54.4M shares outstanding |
54M | 20M |
| May 16, 2022 |
10-Q filing | 54.3M shares outstanding |
54M | 20M |
| Mar 03, 2022 |
10-K filing | 53.3M shares outstanding |
53M | 20M |
| Mar 03, 2022 |
POS AM filing: This is a POS AM filing for a potential offering of common stock, preferred stock, debt securities, warrants, subscription rights and units up to an aggregate amount of $300,000,000, including an at the market offering of common stock through Cowen. |
54M | 20M |
| Nov 04, 2021 |
10-Q filing | 54.1M shares outstanding |
54M | 20M |
| Aug 05, 2021 |
10-Q filing | 54.1M shares outstanding |
54M | 20M |
| May 05, 2021 |
10-Q filing | 54.0M shares outstanding |
54M | 20M |
| Mar 03, 2021 |
10-K filing | 53.8M shares outstanding |
54M | 20M |
| Jan 19, 2021 |
S-1 filing: Passage Bio, Inc. is offering 7,000,000 shares of its common stock in an S-1 filing, with an additional underwriter option to purchase up to 1,050,000 shares. The last reported sale price on January 15, 2021, was $28.24 per share. |
46M | 20M |
| Nov 10, 2020 |
10-Q filing | 45.5M shares outstanding |
46M | 12M |
| Aug 13, 2020 |
10-Q filing | 45.5M shares outstanding |
45M | 12M |
| May 11, 2020 |
10-Q filing | 45.4M shares outstanding |
45M | 12M |
| Feb 27, 2020 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock with an option to purchase additional shares. |
32M | 12M |
| Feb 18, 2020 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The company is offering 7,400,000 shares of common stock, and has granted the underwriters an option to purchase up to 1,110,000 additional shares. Shares outstanding as of January 31, 2020 include 478,578 shares subject to forfeiture or repurchase. |
32M | 8.5M |
| Feb 03, 2020 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock. The filing includes information about the company's financials, risk factors, and the proposed use of proceeds. |
140M | 0 |